Morningstar

DaVita Inc DVA

Morningstar Rating
Unlock
Stock XNYS Rating as of
$159.11 −3.64 (2.24%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

DaVita's Outlook Looks Solid Despite Obesity Drug Threat

Julie Utterback

After selling DaVita Medical Group in 2019, DaVita has focused on providing services to end-stage renal disease, or ESRD, patients primarily in the United States, although its international footprint is expanding organically and through acquisitions. Over several decades, DaVita has built the largest network of dialysis clinics in the US, and although covid-19-related mortality and labor pressures cut into its profits in recent years, we see brighter days ahead for the firm despite some challenges emerging on the obesity drug front.

Read Full Report

Price vs Fair Value

View History
DVA is trading at a 385% premium.
Price
$159.11
Fair Value
$393.00
Uncertainty
High
1-Star Price
$269.50
5-Star Price
$69.20
Economic Moat
Mdxgbnk
Capital Allocation
Mktdqlbh

Bulls Say, Bears Say

Bulls

After recent covid mortality challenges and obesity drug expansion, the ESRD patient population may grow at a healthy rate in the US and around the globe for the long run, which should benefit DaVita.

Bears

Potential US healthcare policy changes could reduce industry profitability if insurance coverage shifts away from employer-based plans and if Medicare reimbursement rates aren't changed significantly.

Show More

News

View All

Trading Information

Previous Close Price
$162.75
Day Range
$158.93–163.06
52-Week Range
$71.51–166.04
Bid/Ask
$158.86 / $159.59
Market Cap
$13.35 Bil
Volume/Avg
709,143 / 711,294

Key Statistics

Price/Earnings (Normalized)
16.42
Price/Sales
1.16
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
7.31%

Company Profile

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.
Sector
Healthcare
Industry
Medical Care Facilities
Stock Style Box
Mid Core
Total Number of Employees
70,000
Website
https://www.davita.com

Competitors

Valuation

View More
Metric
DVA
FMS
THC
Price/Earnings (Normalized)
 16.4214.9416.77
Price/Book Value
 21.390.834.46
Price/Sales
 1.160.590.79
Price/Cash Flow
 7.085.028.85
Price/Earnings
DVA
FMS
THC

Financial Strength

Metric
DVA
FMS
THC
Quick Ratio
 1.060.861.24
Current Ratio
 1.161.461.45
Interest Coverage
 4.603.296.18
Quick Ratio
DVA
FMS
THC

Profitability

Metric
DVA
FMS
THC
Return on Assets (Normalized)
 7.26%2.63%3.49%
Return on Equity (Normalized)
 128.03%6.59%43.46%
Return on Invested Capital (Normalized)
 11.03%4.20%8.17%
Return on Assets
DVA
FMS
THC

Medical Care Facilities Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
HCA Healthcare Inc
HCA
QfmjwqbBhvxz$104.2 Bil
 Fresenius SE & Co KGaA
FSNUF
—Gbtcx$21.3 Bil
 Fresenius SE & Co KGaA ADR
FSNUY
—Bjmkn$21.3 Bil
 Tenet Healthcare Corp
THC
FqhcprzrCyyd$15.5 Bil
 Universal Health Services Inc Class B
UHS
—Cjclmp$14.9 Bil
 Bangkok Dusit Medical Services PCL ADR
BDUUY
—Lzxm$14.8 Bil
 Bangkok Dusit Medical Services PCL Shs Foreign Registered
BDULF
—Hlqrc$14.8 Bil
 Fresenius Medical Care AG
FMCQF
—Qwmmyh$12.4 Bil
 Fresenius Medical Care AG ADR
FMS
HytqtKtzxh$12.4 Bil

Sponsor Center